Trial reportEuropean journal of nutrition2026
Quercetin prophylaxis in prevention of acute mountain sickness (AMS): a randomized, double blind, placebo controlled phase-II clinical trials.
Trial report in European journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAcute Mountain sickness (AMS) is a common form of high altitude illnesses (HAI) primarily caused by hypobaric hypoxia. Proper acclimatization is crucial for enhancing the physiological adaptability during ascent to high altitudes (HA).
aimThe present study aimed to evaluate the effectiveness of quercetin bar prophylaxis in preventing AMS during acclimatization to a high altitude environment.
designA double blind, randomized, placebo-controlled trial.
methodsThe study included 110 healthy lowland male subjects with age 26.86 ± 4.1 years (range between 20 and 40 years), who ascended from near sea level (440 m) to high altitude (3048 m) where they spent 6 days, thereafter further ascended to very high altitude (3750 m). The participants were randomly assigned in to two groups. Placebo group (n = 55, food bar without quercetin; identical in appearance, taste and smell) and Quercetin group (n = 55, food bar containing 500 mg quercetin). Subjects consumed one bar daily for 15 days, beginning two days prior to ascent and continued throughout the study period. Physiological parameters (SpO
resultsQuercetin supplementation significantly reduced the incidence and severity score of AMS compared to placebo. At the end of the study, AMS prevalence was 2% in the quercetin group versus 25% in the placebo group. Arterial oxygen saturation was significantly higher in the quercetin group (94.0 ± 2.0%) compared to the placebo group (90.02 ± 1.0 p < 0.001). Both systolic (8 mm Hg) and diastolic (4 mm Hg) blood pressure were significantly lower in the quercetin group (p < 0.001). Hematological parameters (haemoglobin and haematocrit) showed improvement with quercetin supplementation. Oxidative stress parameters indicated reduced malondialdehyde (MDA) levels (p < 0.001) and maintained reduced glutathione (GSH) levels in plasma of quercetin group. Plasma endothelin-1 (ET-1) levels were significantly reduced in the quercetin group (p < 0.001). No significant differences were observed in body composition parameters (body weight, fat mass, fat percentage and percentage of total body water) between the groups.
conclusionProphylaxis with quercetin bar appears to be effective in reducing the incidence and severity of AMS. It also improves the physiological and haematological responses along with reducing the oxidative stress of the individual ascending to high altitudes.
Indexed as
Identifiers
42435069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.